Abstract: Antibodies to human CD11d, compositions comprising such CD11d antibodies, and methods of using such CD11d antibodies for the treatment of central nervous system trauma including spinal cord injury and traumatic brain injury, as well as systemic inflammatory response following central nervous system trauma.

Abstract: The disclosure relates to means and methods of treating a subject for a CLEC12A positive cancer. In some embodiments the method comprises treating the subject in need thereof with two or more administrations of a bispecific antibody that binds CD3 and CLEC12A, wherein in a first administration an first amount of the bispecific antibody is administered and wherein in each of the subsequent administrations the amount of bispecific antibody is higher than the amount of bispecific antibody in the first administration. In some embodiments CLEC12A positive cancer treatment methods are provided at intervals and dosing regimens that spare hemopoietic stem cell compartment allowing for recovery of normal CLEC12A positive hemopoietic cells.

Abstract: The invention relates to an antibody which binds to cell adhesion molecule 3 (CADM3) or an antibody fragment thereof, a hybridoma which produces the antibody or the antibody fragment thereof, a nucleic acid comprising a nucleotide sequence encoding the antibody or the antibody fragment thereof, a transformant cell comprising a vector comprising the nucleic acid, a method for producing the antibody or the antibody fragment thereof, a composition comprising the antibody or the antibody fragment thereof, and a method for detecting or measuring an antigen present in the brain, a method for diagnosing or treating a brain disease, a method for enhancing the property of accumulating in a brain of an antibody, and a method for increasing the amount of an antibody in the brain, each of which using the antibody or the antibody fragment thereof, and the like.

Abstract: Provided herein are oligomeric reagents, including oligomeric reagents of streptavidin or a streptavidin mutein, compositions thereof, and methods for manufacturing oligomeric reagents, including methods for reliably manufacturing oligomeric particle reagents of a desired size. In some cases, the reagents are oligomeric particle reagents containing a plurality of binding sites for agents, and thus the one or more agents are multimerized by reversibly binding to the oligomeric particle reagent, e.g., thereby creating a multimerized oligomeric particle reagent, having stimulatory agents multimerized thereon. Also provided are methods for using the oligomeric reagents for incubation or culturing, such as to induce stimulation of expansion, activation, and/or survival, of a composition of cells such as a population of lymphocytes.

Abstract: The present disclosure relates to compounds that bind to human GITR, pharmaceutical compositions comprising such compounds, and methods of using such compounds.

Abstract: The present disclosure is directed to antibodies or antigen-binding portions thereof that specifically bind human CCR8, polynucleotides and vectors encoding the same, and pharmaceutical compositions comprising the same. Some aspects of the disclosure are directed to methods of treating a disease or condition comprising administering the anti-CCR8 antibody to a subject in need thereof.

Abstract: Provided herein are novel GPC3 binding domains, and antibodies that include such GPC3 binding domains (e.g., anti-GPC3×anti-CD3). Also provided herein are methods of using such antibodies for the treatment of GPC3-associated cancers.

Abstract: An antibody or Fab fragment, wherein at least one amino group of the N-terminal amino acid of the light chain and/or of the N-terminal amino acid of the heavy chain is bound by an amidic bond to a molecule comprising a fluorophore group A, wherein said bond constitutes at least 70% of the total binding of said molecule to said antibody or Fab.

Abstract: A method for increasing the proportion of a central memory T cell (Tcm) subset in a CAR-T cell product includes adding an artificial antigenic epitope in a CAR, and activating a CAR-T by the artificial antigenic epitope, wherein the artificial antigenic epitope does not exist in other domains or segments of the CAR. A method for preparing a CAR-T cell includes: introducing the CAR into a T cell; and culturing the CAR-introduced T cell, and performing specific activation in the culture process. The preparation method can not only increase the proportion of CAR-positive T cells in the product, but also can achieve specific in vitro amplification of the Tcm subset in the CAR-positive T cells, and significantly increases the proportion of Tcm in a final product. Clinical trials show that the CAR-T cells have significantly improved amplification capacity in vivo, and improved clinical safety and effectiveness.

Abstract: The present invention relates to methods for reducing the heterogeneity of a population of recombinant proteins produced in cell culture, said methods comprising growing host cells producing a recombinant protein in a cell culture medium wherein the cell culture medium comprises one or more cysteine/cystine analogs.

Abstract: Compositions and methods for the detection and diagnosis of Bordetella pertussis are disclosed. Provided are antibodies, or antigen binding fragment thereof, specific for tracheal colonization factor A (TcfA). Also provided are compositions comprising an anti-TcfA antibody of the instant invention and a carrier; and methods for inhibiting, treating, and/or preventing pertussis and/or a B. pertussis infection in a subject in need thereof are provided, comprising administering an anti-TcfA antibody of the instant invention to the subject.

Abstract: The disclosure provides antibody molecules that bind to TCR V? regions and multispecific molecules comprising said antibody molecules. Additionally, disclosed are nucleic acids encoding the same, methods of producing the aforesaid molecules, pharmaceutical compositions comprising aforesaid molecules, and methods of treating a cancer using the aforesaid molecules.

Abstract: A third generation of CAR-CD30 T cells is for treatment of CD30+ Tumors such as lymphoid malignancies, leukemia, and solid tumors. A CD30 chimeric antigen receptor includes, from the N-terminus to the C? terminus, a signal peptide, which is linked by a first linker to an anti CD30 single chain antibody domain from AC10 hybridoma including the AC10 VL sequence and the AC10 VH sequence. The AC10 VL and VH sequences are linked by a second linker.

Abstract: The present invention relates to an antibody binding to lymphocyte activation gene-3 (LAG-3) and use thereof.

Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 102, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.

Abstract: Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload promotes the expression or activity of a functional dystrophin protein. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide, e.g., an oligonucleotide that causes exon skipping in a mRNA expressed from a mutant DMD allele.

Abstract: Provided is a method for producing an antibody-drug conjugate intermediate by addition of acid. An acid additive is used to convert the monomethyl auristatin derivative into a salt thereof to participate in the reaction. The addition of the acid additive can significantly improve the yield of the final product. In addition, the low price of the acid additive greatly reduces the production cost of the final ADC product. Moreover, the method of the present invention adopts a one-step preparation process, in addition to a higher yield of the final product, not only reducing the cost of the consumables, labor, equipment, site, raw materials and the like in the production, but also greatly reducing the production of the waste liquid, and thus reducing production costs and improving production efficiency, and making the method suitable for industrial large-scale production.

Abstract: The present disclosure relates to antibody-drug conjugates (ADCs) wherein one or more active agents are conjugated to an anti-CD19 antibody through a linker. The linker may comprise a unit that covalently links active agents to the antibody. The disclosure further relates to monoclonal antibodies and antigen binding fragments, variants, multimeric versions, or bispecifics thereof that specifically bind CD19, as well as methods of making and using these anti-CD19 antibodies and antigen-binding fragments thereof in a variety of therapeutic, diagnostic and prophylactic indications.

Abstract: The present disclosure provides antibodies that specifically bind to TIGIT. The antibodies have the capacity for substantial activation of T cells and natural killer cells by inhibiting binding of TIGIT to CD155. The antibodies can be used for treatment of cancer and infectious disease, among other applications.

Abstract: Provided herein are populations of anti-CD20 antibody proteins with specified ranges of post-translational modifications. Also provided are methods of using and methods of making such populations of anti-CD20 antibody proteins.